Paradigm Completes Institutional Placement and Prepares Share Purchase Plan

Paradigm Biopharmaceuticals ( (AU:PAR) ) has issued an announcement.

Paradigm Biopharmaceuticals has completed a placement of 73,684,211 fully paid ordinary shares at $0.19 per share to institutional and sophisticated investors, raising new equity capital without a prospectus under Australian Corporations Act provisions. The company confirmed it is compliant with its continuous disclosure and reporting obligations, stated there is no excluded information requiring disclosure, and reiterated plans to conduct a share purchase plan on similar disclosure exemptions, signaling ongoing efforts to broaden its capital base.

The placement and planned share purchase plan underscore Paradigm’s strategy to secure funding from both wholesale and eligible retail investors while leveraging streamlined regulatory pathways. This approach may strengthen its balance sheet, support future development activities, and potentially enhance market liquidity, though it also increases the company’s share count and may dilute existing holdings.

The most recent analyst rating on (AU:PAR) stock is a Buy with a A$0.65 price target. To see the full list of analyst forecasts on Paradigm Biopharmaceuticals stock, see the AU:PAR Stock Forecast page.

More about Paradigm Biopharmaceuticals

Paradigm Biopharmaceuticals is an Australian biotechnology company focused on developing and commercializing pharmaceutical therapies. It targets institutional and sophisticated investors through capital market activities to support its clinical and operational programs in the life sciences sector.

Average Trading Volume: 1,317,472

Technical Sentiment Signal: Sell

Current Market Cap: A$79.06M

For detailed information about PAR stock, go to TipRanks’ Stock Analysis page.